WHO Member States Call For Transparency, Access To Innovation On Cancer Drug Pricing 30/01/2019 by David Branigan, Intellectual Property Watch Leave a Comment A substantive discussion took place at the World Health Organization Executive Board meeting yesterday in response to a recently released WHO report on cancer drug pricing. Among the variety of perspectives expressed, many formed consensus in calling for increased transparency of research and development (R&D) costs and equitable access to innovative cancer drugs.
WHO Holds Discussions On Roadmap For Improving Access To Medicines 29/01/2019 by Catherine Saez, Intellectual Property Watch 2 Comments Unaffordable prices, unavailable medicines, a rising need for accessible noncommunicable diseases treatments – these set the stage as the World Health Organization Executive Board started discussion today on one of the more contentious issues of the week. For the Board’s approval is in particular a roadmap and action plan including a dual strategy based on safety and efficacy of health products, and their affordability.
DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 by Intellectual Property Watch Leave a Comment The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the “Pandemic Response Box”, which offers researchers open access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers “will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation.”
WHO Draft Resolution On Universal Health Coverage Shows Efforts At Consensus 28/01/2019 by Catherine Saez, Intellectual Property Watch 2 Comments With half the world’s population still lacking access to essential health services, World Health Organization Executive Board members this week are working to agree on a resolution indicating ways through which this situation can be alleviated. Discussions are going on outside plenary room as delegates seek agreement on a draft resolution.
WHO’s Access Roadmap And The Art Of Accommodation Of Pharma Interest 26/01/2019 by Intellectual Property Watch 1 Comment The Roadmap to access to medicines, vaccines and other health products (Roadmap) to be discussed at this week’s 144th session of WHO’s Executive Board accommodates vital interest of pharmaceutical TNCs on critical issues such as the approach to access, technical assistance on the use of TRIPS flexibilities and access to biosimilars. Adoption of the Roadmap in its current form very well accommodates the interest of the Pharmaceutical TNCs and therefore one need not expect any proactive steps by WHO towards promoting access after the adoption of the Roadmap.
WHO Director Tedros: Innovation, Digital Health A Major Pillar In WHO Transformation 24/01/2019 by William New, Intellectual Property Watch 1 Comment The World Health Organization is significantly upgrading its focus on digital health and innovation as it moves into a new era, renovating literally every aspect of the organisation, the WHO director general told member states today.
US Complaints About Technology Transfer In China: Negotiating The Endgame 24/01/2019 by Intellectual Property Watch 2 Comments Dean Pinkert writes: The United States Trade Representative (USTR) has been open about its view of the difficulties faced by US companies who claim – generally anonymously – that they have been forced to transfer technology to Chinese entities: “The fact that China systematically implements its technology transfer regime in informal and indirect ways makes it ‘just as effective [as written requirements], but almost impossible to prosecute.’” As I explain in this article, I believe such informality is not merely a barrier to prosecutions; it also presents conceptual challenges for US trade negotiators as they attempt to craft effective means to address the concerns of US companies doing business in China.
European Council Advances SPC Waiver For Generics; Negotiations Coming 16/01/2019 by David Branigan, Intellectual Property Watch Leave a Comment The European Union Council of member states has approved a mandate for negotiations with the EU Parliament concerning a draft regulation aimed at boosting EU-based generic and biosimilar manufacturing for export by providing an exception to the extended intellectual property protection granted by special protection certificates (SPCs). The mandate brings the draft regulation a step closer to adoption, and it also suggests that Parliament’s recent amendments to the regulation are likely be key areas of debate in the negotiations, which are expected to begin in the coming weeks.
Supporting UHC And Better Explaining IP – The 2019 Pharma Industry Agenda 16/01/2019 by Intellectual Property Watch 1 Comment In 2019, IFPMA work will continue to focus on constructive engagement in supporting UHC and working with others to strengthen health care systems. The association will continue to engage with a range of stakeholders, particularly multilateral organizations, to better explain the benefits of IP and exchange ideas to address issues of coverage, capacity, affordability and sustainability of healthcare.
US IP Attachés: China’s IP Policy ‘Hijacked’ By Local Interests In 2018; Bad Faith Filings A ‘Cancer’ 21/12/2018 by William New, Intellectual Property Watch Leave a Comment WASHINGTON, DC – Two out of three United States intellectual property attachés based in China last week had tough words for China’s manipulation of IP policy and law over the past year, suggesting they at times “hijack” the legal process in favour of local interests, and are in a mad rush to become the world’s top patent and trademark filers regardless of quality to the point that it has become a “cancer” on the IP registration system. A third US IP attaché, however, took a friendlier and more patient view of China’s actions, downplaying concerns and urging US companies to allow it to continue.